Scientists explore immune memory of common cold coronaviruses before the SARS-CoV-2 pandemic era

In a recent study published in the Cell Host and Microbe journal, researchers assessed the immune memory of common cold coronaviruses (CCCs) three years before the coronavirus disease 2019 (COVID-19) pandemic.

Study: Immunological memory to Common Cold Coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic. Image Credit: Dragana Gordic/Shutterstock
Study: Immunological memory to Common Cold Coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic. Image Credit: Dragana Gordic/Shutterstock

Background

CCCs are seasonal viruses that fall into two genera: alpha-coronaviruses (CoVs), which include HCoV-NL63 and HCoV-229E, and beta-CoVs, which include HCoVHKU1 and HCoV-OC43, that most usually cause mild diseases in humans.

CCCs are endemic viruses with extensive worldwide distribution and have been circulating for a while among humans. The severe acute respiratory syndrome Coronavirus (SARS-CoV), severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), and the Middle East respiratory syndrome CoV (MERS-CoV) are all CoVs that cause severe illness in humans and are associated phylogenetically with the CCC viruses.

Nevertheless, there is inadequate evidence on the prevalence of memory T cell reaction toward CCC, especially their stability with time. Comprehending the steady-state dynamics of CCC antibody and T cell reactions in people has potential significance, given the sustained SARS-CoV-2 evolution during the COVID-19 pandemic. 

Additionally, CCC immunological memory impacts the outcome of the SARS-CoV-2 infection, and developing a pan-CoV vaccine requires an understanding of this impact.

About the study

In the current work, the researchers examined CD4+ T cell and antibody responses to CCC, other respiratory viruses, and ubiquitous or chronic pathogens throughout a longitudinal analysis spanning six months to three years in pre-COVID-19-pandemic samples of young adults from 2016 to 2019. They characterized CD4+ T cell-selective memory reflexes to the four prototypic widely and endemically circulating CCC viruses, namely 229E, NL63, OC43, and HKU1, across a longitudinal population. As a method, the investigators used ex vivo treatment of peripheral blood mononuclear cells (PBMCs) with peptide libraries that span the whole proteome of each virus.

The team analyzed PBMC samples of 32 subjects from an observational study of Bordetella pertussis. They examined the magnitudes of CD4+ T cell reactions to CCC and other antigens over time. Moreover, immunoglobulin (Ig) binding to recombinant spike (S) receptor-binding domain (RBD) antigens of CCC were examined in matched plasma samples.

Results

The researchers found that about 72% to 81% of participants showed modest immune CD4+ T cell memory reactions to each of the four CCC under investigation, with magnitudes and frequencies coherent with earlier values observed in both cohorts of community and healthcare workers. These values were also comparable to two prior research findings. In addition, these immune reactions harbored a modest level of SARS-CoV-2 cross-reactivity. Interestingly, the CCC-specific response magnitude was similar to the immunodominant and ubiquitous pathogen cytomegalovirus (CMV).

The scientists discovered a consistent and long-lasting T cell and antibody reaction against CCC, corroborated by various recent experimental results. The current findings were also consistent with the longevity of immune reactions to other viral infections, such as SARS-CoV-1 or vaccinia, where antigen-selective cells were found 17 and 50 years after infection, respectively, and with torque teno virus (TTV), which is exceptionally stable for many years after vaccination.

While everyone showed measurable antibody titers to CCC, the team discovered that individuals' levels of T cell reactivity varied. Further, the participants most likely to be linked to pre-existing SARS-CoV-2 immunological reactivity were those with significant CCC T cell reactivity and low antibody titers.

The present data also imply that some people, and not all, bear pre-existing T cell memory reactivity to SARS-CoV-2 due to the level of sequence homology between SARS-CoV-2 and CCC. Besides, the authors suggested that additional factors, including recent exposure, human leukocyte antigen (HLA) kind, or other individualized and environmental factors, could be at play.

Conclusions

The study data showed how a significant and long-lasting immunity to CoVs was maintained in the young adult population throughout time, most likely of repeated prior exposures and maybe sporadic reinfections. The researchers stated that further protection might come from establishing pan-coronavirus vaccines that address SARS-CoV-2 and CCC viruses.

Notably, the study discovered that CCC immune reactions were frequently seen as comparable to those of other common antigens and were long-lasting. Low HLA-DR+CD38+ signals were linked to CCC-specific CD4+ T cell responses, and the size of these responses was not associated with the frequency of CCC infections each year.

Likewise, CCC-specific S RBD-specific IgG reactions remained constant throughout time. Finally, pre-existing SARS-CoV-2 immunity was linked to significant CCC-specific CD4+ T cell reactivity, not antibody titers. 

The authors noted that even if at least a few reinfections might have happened throughout the longitudinal follow-up period, the overwhelming body of data implies that the identified reactivity was linked to memory and lasting reactions.

Journal reference:
Shanet Susan Alex

Written by

Shanet Susan Alex

Shanet Susan Alex, a medical writer, based in Kerala, India, is a Doctor of Pharmacy graduate from Kerala University of Health Sciences. Her academic background is in clinical pharmacy and research, and she is passionate about medical writing. Shanet has published papers in the International Journal of Medical Science and Current Research (IJMSCR), the International Journal of Pharmacy (IJP), and the International Journal of Medical Science and Applied Research (IJMSAR). Apart from work, she enjoys listening to music and watching movies.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Susan Alex, Shanet. (2022, July 26). Scientists explore immune memory of common cold coronaviruses before the SARS-CoV-2 pandemic era. News-Medical. Retrieved on November 24, 2024 from https://www.news-medical.net/news/20220726/Scientists-explore-immune-memory-of-common-cold-coronaviruses-before-the-SARS-CoV-2-pandemic-era.aspx.

  • MLA

    Susan Alex, Shanet. "Scientists explore immune memory of common cold coronaviruses before the SARS-CoV-2 pandemic era". News-Medical. 24 November 2024. <https://www.news-medical.net/news/20220726/Scientists-explore-immune-memory-of-common-cold-coronaviruses-before-the-SARS-CoV-2-pandemic-era.aspx>.

  • Chicago

    Susan Alex, Shanet. "Scientists explore immune memory of common cold coronaviruses before the SARS-CoV-2 pandemic era". News-Medical. https://www.news-medical.net/news/20220726/Scientists-explore-immune-memory-of-common-cold-coronaviruses-before-the-SARS-CoV-2-pandemic-era.aspx. (accessed November 24, 2024).

  • Harvard

    Susan Alex, Shanet. 2022. Scientists explore immune memory of common cold coronaviruses before the SARS-CoV-2 pandemic era. News-Medical, viewed 24 November 2024, https://www.news-medical.net/news/20220726/Scientists-explore-immune-memory-of-common-cold-coronaviruses-before-the-SARS-CoV-2-pandemic-era.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients